

Myasthenia gravis



MG- epidemiology Incidence: 14,8 / mil. inhabitants Prevalence: 191 /mil. inhab. /SR 1.1.2007/ Disease onset: mostly: 30. year (F), 60.-70. year (M) Sex rate F:M= 1,7:1 No hereditary cases, familial increased susceptibility for autoimmune disease (HLA)







MGFA (Foundation of America)- Clinical symptoms scaling (Osserman's classification) I. Ocular form MG II. Ocular + slight generalised MG (limbs /bulbar) III: Moderate weakness of ocular + extraocular muscles (limbs, respiratory, bulbar muscles) IV: Severe weakness of ocular + extraocular muscles V: Respiratory failure, suported ventilation


MG- diagnosis 1. History 2. EMG 3. Lab: serum antibodies anti-Ach-R (75% positivity) 4. Clinical tests: Simpson's test- vertical gaze Seeman's test- dysarthria Gorelick's test pharmacol. Tensilon test: iv. amp. inhib. AchE 5. X-rays chest, mediastinal CT, MRI











MG- therapy Currently - no deaths, previously - 30% mortality 1. Pharmacological: IS + symptomatic th 2. Surgical – thymectomy Pharmacological therapy: Immunosupression: Prednison, Azathioprine, Cyclosporine A Plasma exchange/ or IVIG inhib.ChE (Pyridostigmine, Mestinon)

